Status:
COMPLETED
Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics
Lead Sponsor:
Université de Montréal
Collaborating Sponsors:
Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal
Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal
Conditions:
Schizophrenia
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to understand, with the use of functional magnetic resonance imaging, the neural correlates involved in appetite control and the mechanism of weight gain in patients with ...
Detailed Description
Atypical antipsychotics (AAP) have revolutionize treatment of schizophrenia. They are considered to be more effective in reducing positive and negative symptoms and in improving cognitive deficits. Th...
Eligibility Criteria
Inclusion
- Patients with schizophrenia (DMS-IV)
- 18 to 60 years old
- Right handed
- Begin a treatment with olanzapine and had not received it for at leat 6 months
- Other medication accepted (except antipsychotic)
Exclusion
- concomitant axis-I or axis-II disorders
- unstable medical condition
- Concomitant antipsychotic medications
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00290121
Start Date
September 1 2006
End Date
June 1 2008
Last Update
March 14 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de recherche Fernand-Seguin
Montreal, Quebec, Canada, H1N 3V2